Chart, Financials, Historical Prices, Industry, Insider, Messages, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 9-Feb-2010
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 10)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
6-Feb-10Reuters Investment ProfileN/APaladin Labs Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.12$20  View Abstract
6-Feb-10Reuters Investment ProfileN/APlan B Group Holdings Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.12$20  View Abstract
4-Feb-10Versant PartnersDouglas LoePaladin's cancer pain drug Abstral could be approved by H2/102$10  View Abstract
4-Feb-10Wright ReportsN/AWright Investors Service Comprehensive Report for Paladin Labs Inc41$65  View Abstract
6-Jan-10Global Markets DirectGlobal Markets DirectPaladin Labs Inc. Financial and Strategic Analysis Review21$300  View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Industry Report for DRUGS18$49  View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Industry Report for RETAILING - FOODS18$49  View Abstract
29-Mar-09PriceTarget Research, Inc.N/ADrug Intelligence Monitor: overall outlook VERY STRONG - 25 new Leaders; 10 new Laggards.50$20  View Abstract
29-Mar-09PriceTarget Research, Inc.N/AHealth Care Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards.65$40  View Abstract
28-Mar-09Stock Traders DailyThomas H. Kee Jr.Trading Report for (PLB) Detailed Technical Analysis + Free Market Timing Report15$18  View Abstract
Brokerage Reports (Showing 1 to 1 of 1)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
4-Feb-10Versant PartnersDouglas LoePaladin's cancer pain drug Abstral could be approved by H2/102$10  View Abstract
Independent Reports (Showing 1 to 9 of 9)
Release
Date [down]		 Contributor Author Title Pages Price More Info
6-Feb-10Reuters Investment ProfileN/APaladin Labs Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.12$20View Abstract
6-Feb-10Reuters Investment ProfileN/APlan B Group Holdings Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.12$20View Abstract
4-Feb-10Wright ReportsN/AWright Investors Service Comprehensive Report for Paladin Labs Inc41$65View Abstract
6-Jan-10Global Markets DirectGlobal Markets DirectPaladin Labs Inc. Financial and Strategic Analysis Review21$300View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Industry Report for DRUGS18$49View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Industry Report for RETAILING - FOODS18$49View Abstract
29-Mar-09PriceTarget Research, Inc.N/ADrug Intelligence Monitor: overall outlook VERY STRONG - 25 new Leaders; 10 new Laggards.50$20View Abstract
29-Mar-09PriceTarget Research, Inc.N/AHealth Care Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards.65$40View Abstract
28-Mar-09Stock Traders DailyThomas H. Kee Jr.Trading Report for (PLB) Detailed Technical Analysis + Free Market Timing Report15$18View Abstract

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.